Effects of preexposure to dexfenfluramine, phentermine, dexfenfluramine-phentermine, or fluoxetine on sibutramine-induced hypophagia in the adult rat

Pharmacology Biochemistry and Behavior

Volumn 75, Issue 1, 2003, Pages 103-114

  Wellman, P J ^a   Jones, S L ^a   Miller, D K ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

Drug sensitization; Drug tolerance; Noradrenergic; Obesity; Serotonergic

Indexed keywords

DEXFENFLURAMINE; FLUOXETINE; PHENTERMINE; SEROTONIN UPTAKE INHIBITOR; SIBUTRAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CROSS TOLERANCE; DRUG SENSITIZATION; DRUG TOLERANCE; FLUID INTAKE; FOOD INTAKE; HYPOPHAGIA; MALE; NONHUMAN; NORADRENERGIC SYSTEM; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; WEIGHT REDUCTION;

EID: 0038635939     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(03)00045-5     Document Type: Article

References (43)

1. Anonymous Fenfluramine and dexfenfluramine withdrawn from market. Am. J. Health Syst. Pharm. 54:1997;2260-2269.
2. Balcioglu A., Wurtman R.J. Effects of fenfluramine and phentermine (fen-phen) on dopamine and serotonin release in rat striatum: in vivo microdialysis study in conscious animals. Brain Res. 813:1998;67-72.
3. Balcioglu A., Wurtman R.J. Sibutramine, a serotonin uptake inhibitor, increases dopamine concentrations in rat striatal and hypothalamic extracellular fluid. Neuropharmacology. 39:2000;2352-2359.
4. Bray G.A. Uses and misuses of the new pharmacotherapy of obesity. Ann. Med. 31:1999;1-3.
5. Bray G.A., Blackburn G.L., Ferguson J.M., Greenway F.L., Jain A.K., Mendel C.M.et al. Sibutramine produces dose-related weight loss. Obes. Res. 7:1999;189-198.
6. Buckett W.R., Thomas P.C., Luscombe G.P. The pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant which induces rapid noradrenergic down-regulation. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:1988;575-584.
7. Chapelot D., Marmonier C., Thomas F., Hanotin C. Modalities of the food intake-reducing effect of sibutramine in humans. Physiol. Behav. 68:2000;299-308.
8. Cheetham S.C., Viggers J.A., Slater N.A., Heal D.J., Buckett W.R. [3H]Paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments. Neuropharmacology. 32:1993;737-743.
9. Connoley I.P., Liu Y.L., Frost I., Reckless I.P., Heal D.J., Stock M.J. Thermogenic effects of sibutramine and its metabolites. Br. J. Pharmacol. 126:1999;1487-1495.
10. Cooper S.J. Drugs and hormones: their effects on ingestion. Rowland N.E., Toates F.M. Feeding and drinking. vol. 1:1987;231-270 Elsevier, New York.
11. Curzon G., Gibson E.L., Oluyomi A.O. Appetite suppression by commonly used drugs depends on 5-HT receptors, but not on 5-HT availability. Trends Pharmacol. Sci. 18:1997;21-25.
12. Danforth E. Sibutramine and thermogenesis in humans. Int. J. Obes. 23:1999;1007-1008.
13. Garratini S., Buczko W., Jori A., Samanin R. The mechanism of action of fenfluramine. Postgrad. Med. J. 51:1975;27-35.
14. Gobbi M., Frittoli E., Mennini T., Garattini S. Releasing activities of D-fenfluramine and fluoxetine on rat hippocampal synaptosomes preloaded with [3H]serotonin. Naunyn Schmiedebergs Arch. Pharmacol. 345:1992;1-6.
15. Gobbi M., Crespi D., Foddi M.C., Fracasso C., Mancini L., Parotti L.et al. Effects of chronic treatment with fluoxetine and citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn Schmiedebergs Arch. Pharmacol. 356:1997;22-28.
16. Grignaschi G., Fanelli E., Scagnol I., Samanin R. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats. Br. J. Pharmacol. 127:1999;1190-1194.
17. Gundlah C., Martin K.F., Heal D.J., Auerbach S.B. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents - sibutramine is a reuptake inhibitor. J. Pharmacol. Exp. Ther. 283:1997;581-591.
18. Halladay A.K., Fisher H., Wagner G.C. Interaction of phentermine plus fenfluramine: neurochemical and neurotoxic effects. Neurotoxicology. 19:1998;177-183.
19. Hansen D.L., Toubro S., Stock M.J., Macdonald I.A., Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int. J. Obes. 23:1999;1016-1024.
20. Heal D.J., Aspley S., Prow M.R., Jackson H.C., Martin K.F., Cheetham S.C. Sibutramine: a novel anti-obesity drug. A review of the pharmacological evidence to differentiate it from D-amphetamine and D-fenfluramine. Int. J. Obes. 22(Suppl 1):1998;S18-S28.
21. Heal D.J., Cheetham S.C., Prow M.R., Martin K.F., Buckett W.R. A comparison of the effects on central 5-HT function of sibutramine hydrochloride and other weight-modifying agents. Br. J. Pharmacol. 125:1998;301-308.
22. Jackson H.C., Needham A.M., Hutchins L.J., Mazurkiewiez S.E., Heal D.J. Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat. Br. J. Pharmacol. 121:1997;1758-1762.
23. Jackson H.C., Bearham M.C., Hutchins L.J., Mazurkiewicz S.E., Needham A.M., Heal D.J. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br. J. Pharmacol. 121:1997;1613-1618.
24. Kalia M., O'Callaghan J.P., Miller D.B., Kramer M. Comparative study of fluoxetine, sibutramine, sertraline and dexfenfluramine on the morphology of serotonergic nerve terminals using serotonin immunohistochemistry. Brain Res. 858:2000;92-105.
25. Lancashire B., Viggers J., Prow M.R., Aspley S., Martin K.F., Cheetham S.C.et al. Monoamine release and uptake inhibition profiles of antiobesity agents. J. Psychopharmacology. 12(Suppl A):1998;A36.
26. Lean M.E.J. Sibutramine - a review of clinical efficacy. Int. J. Obes. 21(Suppl 1):1997;S30-S36.
27. Lew R., Weisenberg B., Vosmer G., Seiden L.S. Combined phentermine/fenfluramine administration enhances depletion of serotonin from central terminal fields. Synapse. 26:1997;36-45.
28. Liu Y.-L., Heal D.J., Stock M.J. Mechanism of the thermogenic effect of metabolite 2 (BTS 54 505), a major pharmacologically active metabolite of the novel anti-obesity drug sibutramine. Int. J. Obes. 26:2002;1245-1253.
29. Luscombe G.P., Hopcroft R.H., Thomas P.C., Buckett W.R. The contribution of metabolites to the rapid and potent down-regulation of rat cortical B-adrenoceptors by the putative antidepressant sibutramine hydrochloride. Neuropharmacology. 28:1989;129-134.
30. McCann U.D., Yuan J., Ricaurte G.A. Neurotoxic effects of +/-fenfluramine and phentermine, alone and in combination, on monoamine neurons in the mouse brain. Synapse. 30:1998;239-246.
31. McNeely W., Goa K.L. Sibutramine: a review of its contributions to the management of obesity. Drugs. 56:1998;1093-1124.
32. Mitchell J.C., Jackson H.C., Heal D.J. Effect of monoamine antagonists on aminorex, phentermine, and D-amphetamine hypophagia. J. Psychopharmacol. 12(Suppl A):1998;38.
33. Prow M.R., Lancashire B., Aspley S., Heal D.J., Kilpatrick I.C. Additive effects on rat brain 5HT release of combining phentermine with dexfenfluramine. Int. J. Obes. Relat. Metab. Disord. 25:2001;1450-1453.
34. Roth J.D., Rowland N.E. Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats. Psychopharmacology. 137:1998;99-106.
35. Roth J.D., Rowland N.E. Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy? Eur. J. Pharmacol. 373:1999;127-134.
36. Rothman R.B., Baumann M.H., Dersch C.M., Romero D.V., Rice K.C., Carroll F.I.et al. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse. 39:2001;32-41.
37. Rowland N.E., Marshall M., Roth J.D. Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats. Psychopharmacology. 149:2000;77-83.
38. Strack A.M., Shu J., Camacho R., Gorski J.N., Murphy B., MacIntyre D.E.et al. Regulation of body weight and carcass composition by sibutramine in rats. Obes. Res. 10:2002;173-181.
39. Tao T., Aspley A., Brammer R., Heal D., Auerbach S. Effects on serotonin in rat hypothalamus of D-fenfluramine, aminorex, phentermine and fluoxetine. Eur. J. Pharmacol. 445:2002;69-81.
40. Van Gaal L.F., Wauters M.A., De Leeuw I.H. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment. Exp. Clin. Endocrinol. Diabetes. 106(Suppl 2):1998;35-40.
41. Wellman P.J. Norepinephrine and the control of food intake. Nutrition. 16:2000;837-842.
42. Wellman P.J., Maher T.J. Synergistic interactions between fenfluramine and phentermine. Int. J. Obes. Relat. Metab. Disord. 23:1999;723-732.
43. Wellman P.J., Davies B.T., Morien A., McMahon L. Modulation of feeding by hypothalamic paraventricular nucleus alpha 1- and alpha 2-adrenergic receptors. Life Sci. 53:1993;669-679.